Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004688
Status:
COMPLETED
Last Update Posted:
2015-03-25
First Post:
2000-02-24
Brief Title:
Phase II Study of Carmustine Streptozocin and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
Sponsor:
Emory University
Organization:
FDA Office of Orphan Products Development
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
1999-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVES
I Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine streptozocin and mercaptopurine
I Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine streptozocin and mercaptopurine
Detailed Description:
PROTOCOL OUTLINE
Patients receive mercaptopurine IV on days 1-3 carmustine by continuous infusion on days 3-5 and streptozocin IV over 20 minutes on days 2-5 Patients receive treatment every 42 days for up to 4 courses
Completion date provided represents the completion date of the grant per OOPD records
Patients receive mercaptopurine IV on days 1-3 carmustine by continuous infusion on days 3-5 and streptozocin IV over 20 minutes on days 2-5 Patients receive treatment every 42 days for up to 4 courses
Completion date provided represents the completion date of the grant per OOPD records
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUSM-FDR001274 | None | None | None |